ALKS: Alkermes Inc. plc Company Profile & Statistics

About

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Info & Links

CEO

Richard F. Pops

Headquarters

1 BURLINGTON ROAD,CONNAUGHT HOUSE
DUBLIN, L2 D04 C5Y6, IRELAND

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

1,800

Alkermes Inc. plc Statistics

Valuation Measures

Market Capitalization²

5.42B

Enterprise Value

5.13B

Enterprise Value/EBITDA(ttm)

11.41

Price to Earnings Ratio(ttm)

14.67

Price to Sales(ttm)

3.71

Price to Book(mrq)

3.92

Price to Cash(ytd)

13.39

Profitability

Gross Margin(ttm)

84.18%

Operating Margin(ttm)

26.18%

Profit Margin(ttm)

22.98%

Return on Equity(ttm)

30.80%

Return on Invested Capital(ttm)

24.38%

Return on Assets(ttm)

19.09%

Income Statement

Revenue(ttm)

1.56B

Revenue Per Share(ttm)

9.58

Gross Profit(ttm)

1.31B

EBITDA(ttm)³

449.17M

Net Income Available to Common(ttm)

367.07M

Diluted EPS(ttm)

2.17

Share Statistics

Beta (5Y Monthly)

0.49

52-Week Change

16.60%

S&P 500 52-Week Change

12.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

162.61M

Dividend Yield

0.00%

Float⁴

154.66M

% Held by Insiders

4.89%

% Held by Institutions

95.21%

Balance Sheet

Total Cash(mrq)

751.67M

Total Cash Per Share(mrq)

4.62

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.04%

Quick Ratio(mrq)

2.65%

Book Value Per Share(mrq)

9.03

Cash Flow

Operating Cash Flow Per Share(ytd)

2.60

Free Cash Flow(ytd)

406.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

ALKS

Alkermes Inc. plc

Alkermes Inc. plc Profile